KRSA Stock Forecast: Korsana Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$38
+7.14% on the day

The 6 Wall Street analysts covering Korsana Biosciences, Inc. hold a median 12-month price target of $44 — +15.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7B
Ticker Nerd rank
24/ 100
Median analyst target
$44
Analysts covering
6
Revenue$0.0−100.0% y/y
Operating income−$1.8M
Net income−$1.8M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+20.0%
1M
+22.4%
YTD
+327.2%
1Y
+282.1%
From 52W high
−15.0%
From 52W low
+402.4%
$8
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Korsana Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
88
Value
83
Quality
45
Volatility
31
Accruals
26
Revisions
22
Growth
20
Issuance
15

Momentum (88): The shares have been drifting up relative to others.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KRSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KRSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26KRSAHigh $70Median $44Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$8
Low
$44
Median
$70
High

The green dot is the last close — the median target sits +15.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026Wells FargoInitiatesOverweight$44
5 Oct 2026WedbushInitiatesOutperform$44
28 Sept 2026GuggenheimInitiatesBuy$70
14 Sept 2026StifelInitiatesBuy$43
14 Sept 2026TD CowenInitiatesBuy—
11 Sept 2026UBSInitiatesBuy$55
20 Oct 2021Truist SecuritiesInitiatesBuy$14
24 Sept 2021Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KRSA.

Market Radar

This page is one stock. Monday covers all of them.

KRSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KRSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Korsana Biosciences, Inc. returned +282.1% against +6.9% for the S&P 500, dividends included.

KRSA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26KRSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KRSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.9×

Cheaper than 31% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−23.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Korsana Biosciences, Inc. has a market value of $1.7B and an enterprise value of $267.8M.

  • Revenue in the twelve months to 30 June 2026: $1.9M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$6.7M, a −353.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$4.5M.

  • Shares outstanding: 45.5M.

  • Korsana Biosciences, Inc. employs 19 people — $100K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

KRSA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KRSAKorsana Biosciences, Inc.$1.7B24
MAZEMaze Therapeutics, Inc.$1.7B25
BRVEBraveheart Bio, Inc.$1.7B1
TRAXFirst Tracks Biotherapeutics, Inc.$1.7B4
STOKStoke Therapeutics, Inc.$1.8B43
FTREFortrea Holdings, Inc.$1.8B92
AGIOAgios Pharmaceuticals, Inc.$1.7B87

Take a look at KRSA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Korsana Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about KRSA

What is the KRSA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Korsana Biosciences, Inc. have a median 12-month price target of $44, with estimates ranging from $8 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KRSA stock a buy right now?

Of the 6 analysts covering Korsana Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Korsana Biosciences, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KRSA?

As at 21 Nov 2026, Korsana Biosciences, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).

Will KRSA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +15.9% from the last close, and Ticker Nerd's factor model ranks Korsana Biosciences, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KRSA stock forecast for 2030?

No analyst covering Korsana Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $70 over the next 12 months.

How has KRSA stock performed over the past year?

Korsana Biosciences, Inc. returned +282.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Korsana Biosciences, Inc. do?

Korsana Biosciences, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Alzheimer’s disease. Its work centers on THETA, a proprietary blood-brain barrier shuttle platform designed to improve delivery of large therapeutic molecules into the central nervous system.

Company

About Korsana Biosciences, Inc.

Korsana Biosciences, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, with an initial emphasis on Alzheimer’s disease. Its work centers on THETA, a proprietary blood-brain barrier shuttle platform designed to improve delivery of large therapeutic molecules into the central nervous system. The company’s current pipeline includes THETA-enabled antibody programs aimed at addressing disease biology in the brain, including an anti-amyloid beta approach for Alzheimer’s disease. Korsana Biosciences operates in the health care and life sciences sector, where its role is to advance precision-engineered biologics for central nervous system disorders. The company is based in Waltham, Massachusetts.

CEO Dr. Jonathan Violin M.B.A., Ph.D. · 19 employees · United States · https://korsana.com